Published online Aug 26, 2022. doi: 10.12998/wjcc.v10.i24.8718
Peer-review started: March 14, 2022
First decision: May 11, 2022
Revised: May 24, 2022
Accepted: July 16, 2022
Article in press: July 16, 2022
Published online: August 26, 2022
Processing time: 155 Days and 0.2 Hours
Myasthenia gravis (MG) is an autoimmune disorder caused by neuromuscular junction failure characterized by muscle weakness and fatigability. We herein report a case of MG that received intravascular laser irradiation of blood (ILIB) interventions and regained muscle power and better quality of life. To our knowledge, no previous study has investigated the benefits of ILIB treatment on patients with MG. We also evaluated the changes in brain perfusion scan and the MG activities of daily living (MG-ADL) and quantitative MG (QMG) scales.
A 59-year-old man presented to our outpatient hospital experiencing ptosis, diplopia, fibromyalgia, muscle fatigue, and fluctuating weakness in his limbs for 1 year. Based on his history, physical examination, and laboratory investigations, the final diagnosis was a flare-up of MG with poor endurance and muscle fatigue. The patient agreed to receive ILIB. Brain single-photon emission computed tomography (SPECT) was performed both before and after ILIB therapy. After receiving three courses of ILIB, the brain SPECT images showed greatly increased perfusion of the frontal lobe and anterior cingulate gyri. The patient’s MG-ADL scale score decreased markedly from 17/24 to 3/24. The QMG scale score also decreased remarkably from 32/39 to 9/39. The symptoms of MG became barely detectable and the patient was able to perform his activities of daily living and regain muscle power.
ILIB might have beneficial effects on MG, and brain SPECT images provided direct evidence of a positive correlation between ILIB and clinical performance.
Core Tip: Myasthenia gravis (MG) is an autoimmune disease without effective treatments. We herein report a case of intractable MG administered a novel therapy, intravascular laser irradiation of blood interventions (ILIB), which regained muscle power and improved quality of life. To our knowledge, this is the first study investigating the benefits of ILIB treatment in patients with MG. We also evaluated the changes in brain perfusion scan and MG activities of daily living scale, and quantitative MG scale scores. We report this case to trigger further research and facilitate the recovery of patients with MG.